BioSpace News Archive

Nectero Medical today announced initiation of a Phase II/III clinical trial (stAAAble) to investigate the safety and efficacy of the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System in patients with infrarenal abdominal aortic aneurysms (AAAs), maximum diameter 3.5 – 5.0cm.

Accelus announced that it has received a significant financial investment through a $20 million debt facility from Symbiotic Capital.

Gemini BioProducts Holding, Inc. announced the appointment of Steven Sandoval, Sr., to its Board of Directors.

eGenesis and OrganOx today announced the successful completion of an extracorporeal perfusion of a brain-dead research donor using a genetically engineered porcine liver.

TransCode Therapeutics, Inc. today announced the pricing of a public offering of an aggregate of 5,942,623 shares of its common stock (or common stock equivalents) and warrants to purchase up to 11,885,246 shares of common stock at a combined public offering price of $1.22 per share.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that RareCyte Inc., a precision biology company based in Seattle, Washington, is live on SOPHiA GENETICS.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced a strategic reduction of its workforce by approximately 30%.

QIAGEN N.V. announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split.

NextCure, Inc. (Nasdaq: NXTC) today announced the presentation of preclinical data relating to a novel humanized monoclonal antibody targeting VSTM-1, for the treatment of progressive inflammatory airway disorders, including chronic obstructive pulmonary disease (COPD), at the Keystone Symposium for Inhibitory Receptors in Immune Homeostasis, Disease and Therapy.

AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS) today presented new clinical and pre-clinical data for ABP-450 in treating cervical dystonia (CD) and posttraumatic stress disorder (PTSD) at TOXINS 2024, a leading conference held by the International Neurotoxin Association (INA) from January 17th - 20th at the Estrel Berlin in Berlin, Germany.